💡 Finnish company Nordic Bioproducts Group has opened its first production facility in Lappeenranta. The facility will produce microcrystalline cellulose and other cellulose derivatives with the start-up’s AaltoCell technology. The facility is expected to create €40m in revenue in its first full operating year. It will use a fraction of the chemicals, water, and electricity compared to traditional production processes and achieve a 72% reduction in greenhouse gas emissions.
📢 Nordic Bioproducts Group Revolutionizes Cellulose Production: Game-Changing Facility Unveiled
Introduction:
Finnish Nordic Bioproducts Group has opened a production facility to produce advanced cellulosic materials with the start-up’s AaltoCell technology.
Main points:
- Nordic Bioproducts Group’s production facility in Lappeenranta is the first of its kind and represents a significant leap in manufacturing and enabling continuous and sustainable production at scale.
- The facility will produce microcrystalline cellulose (MCC) and other cellulose derivatives with zero solid waste and a significant reduction in greenhouse gas emissions compared to traditional methods.
- Microcrystalline cellulose and other cellulose derivatives have various applications across industries and contribute to environmental sustainability by replacing non-sustainable substances.
- The chosen location in Lappeenranta provides proximity to existing pulp manufacturing plants, local supply, and short access to seaports for secure supply chain management.
- The production facility started its first phase in March 2024 and is expected to triple its revenue in the next three years. Nordic Bioproducts Group aims to expand its workforce and welcome clients from various industries and countries.
Conclusion:
Nordic Bioproducts Group’s new production facility in Lappeenranta is set to revolutionize the manufacturing of advanced cellulosic materials. The facility’s sustainable production methods and versatile cellulose derivatives offer a valuable solution for various industries while reducing greenhouse gas emissions and promoting environmental sustainability. The facility’s strategic location ensures a secure supply chain and positions Nordic Bioproducts Group for future growth and global partnerships.
